PT - JOURNAL ARTICLE AU - Cornelis, Stéphanie S. AU - Bauwens, Miriam AU - Haer-Wigman, Lonneke AU - De Bruyne, Marieke AU - Pantrangi, Madhulatha AU - De Baere, Elfride AU - Hufnagel, Robert B. AU - Dhaenens, Claire-Marie AU - Cremers, Frans P.M. TI - Compendium of clinical variant classification for 2,247 unique <em>ABCA4</em> variants to improve genetic medicine access for Stargardt Disease AID - 10.1101/2023.04.24.23288782 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.24.23288782 4099 - http://medrxiv.org/content/early/2023/04/26/2023.04.24.23288782.short 4100 - http://medrxiv.org/content/early/2023/04/26/2023.04.24.23288782.full AB - Biallelic variants in ABCA4 cause Stargardt disease (STGD1), the most frequent heritable macular disease. Determination of the pathogenicity of variants in ABCA4 proves to be difficult due to 1) the high number of benign and pathogenic variants in the gene; 2) the presence of complex alleles; 3) the extensive variable expressivity of this disease and 4) reduced penetrance of hypomorphic variants. Therefore, the classification of many variants in ABCA4 is currently of uncertain significance. Here we complemented the ABCA4 Leiden Open Variation Database (LOVD) with data from ∼11,000 probands with ABCA4-associated inherited retinal diseases from literature up to the end of 2020. We carefully adapted the ACMG/AMP classifications to ABCA4 and assigned these classifications to all 2,247 unique variants from the ABCA4 LOVD to increase the knowledge of pathogenicity. In total, 1,247 variants were categorized with a Likely Pathogenic or Pathogenic classification, whereas 194 variants were categorized with a Likely Benign or Benign classification. This uniform and improved structured reclassification, incorporating the largest dataset of ABCA4-associated retinopathy cases so far, will improve both the diagnosis as well as genetic counselling for individuals with ABCA4-associated retinopathy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the following funders: Stephanie S. Cornelis and Frans P.M. Cremers were supported by the Foundation Fighting Blindness USA [grant numbers BR-GE-1018-0738-RAD, BR-GE-0120-0775-LUMC], RetinaUK, [grant number GR591], the Fighting Blindness Ireland [grant number FB18CRE], and the Foundation Fighting Blindness USA [grant number PPA-0517-0717-RAD], the Stichting Blindenhulp, the Stichting voor Ooglijders, the Stichting tot Verbetering van het Lot der Blinden, ProRetina, Germany. C.M. Dhaenens was supported by Groupement de Cooperation Sanitaire Interregional G4 qui reunit les Centres Hospitaliers Universitaires Amiens, Caen, Lille et Rouen (GCS G4) and by the Fondation Stargardt France. Elfride De Baere, Frans P.M. Cremers, and Miriam Bauwens were supported by European Union's Horizon 2020 research and innovation programme Marie Sklodowska-Curie Innovative Training Networks (ITN) StarT [grant number 813490]. Elfride De Baere, Frans P.M. Cremers, and Miriam Bauwens were supported by EJPRD19-234 (Solve-RET). Elfride De Baere is a Senior Clinical Investigator of the Research Foundation-Flanders (FWO) (1802220N). Elfride De Baere and Frans P.M. Cremers are members of the ERN-EYE consortium, which is co-funded by the Health Program of the European Union under the Framework Partnership Agreement [grant number 739534-ERN-EYE]. Elfride De Baere was supported by grants from Ghent University Special Research Fund (BOF20/GOA/023); FWO research project G0A9718N, Foundation JED, Foundation John W. Mouton Pro Retina. Robert B. Hufnagel is funded by intramural funds at the National Eye Institute, National Institutes of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We made use of published data present in literature which was found in pubmed. All data were uploaded to https://databases.lovd.nl/shared/genes/ABCA4I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe collected data from affected individuals from literature used to support the findings of this study have been deposited in the ABCA4-LOVD: www.lovd.nl/ABCA4. Additional data produced in the present study are available upon reasonable request.